Protagonist Therapeutics (PTGX) Expected to Announce Quarterly Earnings on Friday

Protagonist Therapeutics (NASDAQ:PTGX) is expected to be announcing its Q4 2025 results before the market opens on Friday, February 20th. Analysts expect the company to announce earnings of ($0.53) per share and revenue of $14.9160 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 12:30 PM ET.

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $82.99 on Thursday. The firm’s 50-day moving average is $84.80 and its 200-day moving average is $75.37. The company has a market cap of $5.19 billion, a price-to-earnings ratio of 133.86 and a beta of 2.26. Protagonist Therapeutics has a 52-week low of $33.70 and a 52-week high of $96.54.

Insider Activity

In other Protagonist Therapeutics news, insider Arturo Md Molina sold 13,151 shares of the stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $82.42, for a total transaction of $1,083,905.42. Following the completion of the transaction, the insider directly owned 84,115 shares in the company, valued at $6,932,758.30. This represents a 13.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Dinesh V. Ph D. Patel sold 34,438 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $82.48, for a total transaction of $2,840,446.24. Following the completion of the sale, the chief executive officer owned 580,505 shares in the company, valued at $47,880,052.40. This represents a 5.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 203,167 shares of company stock valued at $16,889,199. 4.90% of the stock is owned by company insiders.

Institutional Trading of Protagonist Therapeutics

Hedge funds have recently modified their holdings of the company. Greenline Wealth Management LLC acquired a new position in shares of Protagonist Therapeutics in the 4th quarter worth approximately $27,000. Osaic Holdings Inc. boosted its stake in Protagonist Therapeutics by 79.5% in the second quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock worth $65,000 after purchasing an additional 525 shares in the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Protagonist Therapeutics during the third quarter worth $90,000. Truvestments Capital LLC grew its holdings in shares of Protagonist Therapeutics by 60.8% during the fourth quarter. Truvestments Capital LLC now owns 1,161 shares of the company’s stock worth $101,000 after purchasing an additional 439 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Protagonist Therapeutics by 23.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,727 shares of the company’s stock worth $151,000 after purchasing an additional 324 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on PTGX shares. Truist Financial boosted their price target on Protagonist Therapeutics from $88.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, January 5th. JPMorgan Chase & Co. boosted their price objective on Protagonist Therapeutics from $68.00 to $81.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Citigroup upped their target price on Protagonist Therapeutics from $98.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Jefferies Financial Group raised their target price on Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. Finally, Weiss Ratings lowered shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $93.38.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.